Jonathan Wosen

The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to back biotechs in this space.

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, reported positive results in a new study.

U.S. government officials will offer support in 50 countries, most of them located in Africa and Asia, to help prevent future outbreaks.

The European Patent Office has declared an mRNA patent owned by Moderna invalid, a win for Pfizer and BioNTech in their ongoing feud.

The unraveling of regenerative medicine firm Histogen provides a glimpse into conversations other biotechs are undoubtedly having behind closed doors.

From San Diego to Boston, the biotech industry’s demand for space has lessened as public and private investment in companies has slowed.

Public-private partnerships that include modeling experts can be a trusted source of information during a pandemic and beyond.

Clinical trials in the U.S. have long skewed toward recruiting mostly white people. That justifies closely examining what this means for non-white people — and rethinking what we mean by diversity, writes @ArthurCaplan.

Leaders across the health care value chain and in every aspect of its business must embrace sustainability and leverage technological innovations now to decarbonize health care.

The health effects of exposures to low-dose radiation aren’t well understood but should be. An expanded research program is needed to change that.